Response Adaptive Randomization Using Biomarkers with Exponentially Decreasing Probability Sequence
DOI:
https://doi.org/10.6000/1929-6029.2025.14.28Keywords:
Biomarker, Clinical trials, Exponentially decreasing probability sequence, Rare diseases, Response adaptive randomizationAbstract
In this article, it is proposed to study the application of Response Adaptive Randomization (RAR) design in clinical trials. The approach involves the prediction of treatment outcomes based on the biomarker of patients using a regression model. The focus is on rare diseases to efficiently allot the patients among various treatments so as to ensure not only the clinical rights but also the maximum possible benefits to the patients even when they are in clinical trials. Initially, the method uses conventional equal randomization to understand how well every treatment works in patients and this initial duration is known as burn-in period. The proposed work allocates patients to treatments by using an exponentially decreasing probability sequence instead of the existing linearly decreasing sequence to have higher allocation probability to the efficient treatment. In the case of rare disease, it is observed from simulation study that the use of exponentially decreasing probability sequence in RAR design increases the benefit to the patients in the clinical trials when compared to the existing method that uses linearly decreasing sequence. The study also investigates the performance of the proposed RAR design when used with different regression methods under various scenarios. The performance of the proposed design is measured by the proportion of patients assigned to the best treatment in addition to Type I error and power. From the impressive results, it is suggested that the proposed RAR design can be implemented practically in clinical trials of rare diseases without any apprehension.
References
Ravichandran J, Deepa S. Process capability indices for processes when the underlying data are interval-valued. International Journal of Statistics in Medical Research 2024; 13: 210-218. DOI: https://doi.org/10.6000/1929-6029.2024.13.19
Vera-Ponce VJ, Zuzunaga-Montoya FE, Sanchez-Tamay NM, Vásquez-Romero LEM, Loayza-Castro JA, Huaman-Vega CH, Tapia-Limonchi R, De Carrillo CIG. Sample Size and Statistical Power Calculation in Multivariable Analyses: Development and Implementation of "Sample Size Multi" Packages in R. International Journal of Statistics in Medical Research 2024; 13: 259-274. DOI: https://doi.org/10.6000/1929-6029.2024.13.24
Cao Y, Liang J. Multiple mean comparison for clusters of gene expression data through the t-SNE Plot and PCA dimension reduction, International Journal of Statistics in Medical Research 2025; 14: 1-14. DOI: https://doi.org/10.6000/1929-6029.2025.14.01
Jackson H, Bowen S, Jaki T. Using biomarkers to allocate patients in response-adaptive clinical trial. Communications in Statistics-Simulation and Computation 2023; 52(12): 5946-5965. DOI: https://doi.org/10.1080/03610918.2021.2004420
Barnett HY, Villar SS, Geys H, Jaki T. A novel statistical test for treatment differences in clinical trials using a response-adaptive forward-looking Gittins Index Rule. Biometrics 2023; 79(1): 86-97. DOI: https://doi.org/10.1111/biom.13581
Tang F, Gajeswki BJ. Comparative effectiveness research using Bayesian adaptive design for rare diseases: Response adaptive randomization reusing participants. Statistics in Biopharmaceutical Research 2023; 15(1): 154-163. DOI: https://doi.org/10.1080/19466315.2021.1961854
Jennison C, Turnbull BW. Group Sequential Methods with Applications to Clinical Trials. Chapman and Hall/CRC. U.K. 2000. DOI: https://doi.org/10.1201/9781584888581
Rosenberger WF, Stallard N, Ivanova A, Harper CN, Ricks ML. Optimal adaptive designs for binary Response trials. Biometrics 2004; 57(3): 909-913. DOI: https://doi.org/10.1111/j.0006-341X.2001.00909.x
Hu F, Zhang LX, Cheung SH, Chan WS. Doubly adaptive biased coin designs with delayed responses. The Canadian Journal of Statistics 2008; 36(4): 541-549. DOI: https://doi.org/10.1002/cjs.5550360404
Robertson DS, Lee KM, Lopez-Kolkovska BC, Villar SS. Response-adaptive randomization in clinical trials: From myths to practical considerations. Statistical Science 2023; 38(2): 185-208. DOI: https://doi.org/10.1214/22-STS865
Cheung YK, Inoue LY, Wathen JK, Thall PF. Continuous Bayesian adaptive randomization based on event times with covariates. Statistics in Medicine 2006; 25(1): 55-70. DOI: https://doi.org/10.1002/sim.2247
Proschan M, Evans S. Resist the temptation of response adaptive randomization. Clinical Infectious Diseases 2020; 1(11): 3002-3004. DOI: https://doi.org/10.1093/cid/ciaa334
Rosenberger WF, Vidyashankar AN, Agarwal DK. Covariate adjusted response-adaptive designs for binary response. Journal of Biopharmaceutical Statistics 2001; 11(4): 227-236. DOI: https://doi.org/10.1081/BIP-120008846
Villar SS, Rosenberger WF. Covariate-adjusted response-adaptive randomization for multi-arm clinical trials using a modified forward-looking Gittins index rule. Biometrics 2018; 74(1): 49-57. DOI: https://doi.org/10.1111/biom.12738
Thall PF, Wathen JK. Covariate-adjusted adaptive randomization in a sarcoma trial with multi-stage treatments. Statistics in Medicine 2005; 24(13): 1947-1964. DOI: https://doi.org/10.1002/sim.2077
Freidlin B, McShane LM, Korn EI. Randomized clinical trials with biomarkers: Design issues. Journal of the National Cancer Institute 2010; 102(3): 152-160. DOI: https://doi.org/10.1093/jnci/djp477
Hu C, Dignam JJ. Biomarker-driven oncology clinical trials: Key design elements, types, features and practical considerations. Statistical Methods in Precision Oncology: Special Series 2019; 1-12. DOI: https://doi.org/10.1200/PO.19.00086
Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. Biostatistics 2019; 20(2): 273-286. DOI: https://doi.org/10.1093/biostatistics/kxx069
Yang Y, Zhu D. Randomized allocation with nonparametric estimation for a multi-armed bandit problem with covariates. The Annals of Statistics 2002; 30(1): 100-121. DOI: https://doi.org/10.1214/aos/1015362186
Park Y. Challenges and opportunities in biomarker-driven trials: adaptive randomization. Annals of Translational Medicine 2022; 10(18): 1035. DOI: https://doi.org/10.21037/atm-21-6027
Sechidis K, Papangelou K, Metcalfe PD, Svensson D, Weatherall J, Brown G. Distinguishing prognostic and predictive biomarkers: An information theoretic approach. Bioinformatics 2018; 34(19): 3365-76. DOI: https://doi.org/10.1093/bioinformatics/bty357
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Policy for Journals/Articles with Open Access
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are permitted and encouraged to post links to their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work
Policy for Journals / Manuscript with Paid Access
Authors who publish with this journal agree to the following terms:
- Publisher retain copyright .
- Authors are permitted and encouraged to post links to their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work .
